| Bode, Bruce |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
| Completed | 2 | 265 | Europe, Canada, US, RoW | INV-202, None applicable, Placebo | Inversago Pharma Inc., Worldwide Clinical Trials | Diabetic Kidney Disease | 08/24 | 09/24 | | |
| Active, not recruiting | 2 | 140 | Europe, US, RoW | Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo | Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a. | Recent Onset type1 Diabetes | 04/24 | 04/26 | | |
| Recruiting | N/A | 20 | US | Experimental prospective single arm evaluating the Medtronic Duo Extended Set, Medtronic DUO Extended Set with 670G Pump Therapy | Atlanta Diabetes Associates, Medtronic | Diabetes Mellitus, Type 1 | 10/21 | 11/21 | | |
NCT04809285: Use of the Guardian™ Connect System With Smart Connected Devices |
|
|
| Completed | N/A | 217 | US | Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app | Medtronic Diabetes | Type 1 Diabetes Mellitus | 09/23 | 09/23 | | |
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® |
|
|
| Completed | N/A | 244 | US | MiniMed 780G System | Medtronic Diabetes, Eli Lilly and Company | Type 1 Diabetes | 01/24 | 01/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05908448: The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | N/A | 134 | US | 13 CGM (continuous glucose monitor) | Sinocare, Atlanta Diabetes Associates | T1DM - Type 1 Diabetes Mellitus | 10/24 | 11/24 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® |
|
|
| Completed | N/A | 240 | Canada, US, RoW | MiniMed 780G System | Medtronic Diabetes | Type 1 Diabetes | 06/24 | 06/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Blevins, Thomas C |
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections |
|
|
| Completed | 3 | 730 | Europe, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 02/24 | 02/24 | | |
| Active, not recruiting | 3 | 75 | Europe, Canada, Japan, US, RoW | Plozasiran, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Familial Chylomicronemia | 04/24 | 04/26 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes |
|
|
| Completed | N/A | 319 | Canada, US | t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type 2 Diabetes Treated With Insulin | 09/24 | 09/24 | | |
| Ozer, Kerem |
MATILDA, NCT05632276: A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds |
|
|
| Completed | N/A | 54 | US | ConvaFoam, ConvaFoam Silicone, ConvaFoam Border, ConvaFoam Non Adhesive | ConvaTec Inc. | Surgical Wound, Trauma-related Wound | 03/24 | 03/24 | | |
NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System |
|
|
| Withdrawn | N/A | 59 | US | Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System | ConvaTec Inc. | Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound | 10/23 | 10/23 | | |
| Maxson, Amanda |
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome |
|
|
| Recruiting | 3 | 134 | US | Pitolisant tablet, pitolisant, Placebo tablet, placebo | Harmony Biosciences, LLC | Prader-Willi Syndrome | 07/26 | 07/27 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
